460 On Other Exchanges
Symbol
Exchange
460 is not on other exchanges.

sihuan pharmaceutical hldgs (460) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SIHUAN PHARMACEUTICAL HLDGS (460)
\

Related News

No related news articles were found.

sihuan pharmaceutical hldgs (460) Related Businessweek News

No Related Businessweek News Found

sihuan pharmaceutical hldgs (460) Details

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebral vascular system, nervous system, metabolism, anti-infective, and oncology drugs in various formulations and dosages, as well as digestive, CNS, and other drugs. It also engages in the marketing of pharmaceutical products; manufacture of pharmaceutical materials; project preparation for the manufacture of pharmaceutical products; sale of medical supplies and medical appliances; promotion of technology and consulting; and construction of medical projects, as well as the provision of information support, research and development, technology and consulting, and general hospital services. The company was founded in 2001 and is headquartered in Beijing, the People’s Republic of China. Sihuan Pharmaceutical Holdings Group Ltd. is a subsidiary of Plenty Gold Enterprises Limited.

3,292 Employees
Last Reported Date: 09/18/17
Founded in 2001

sihuan pharmaceutical hldgs (460) Top Compensated Officers

Chief Executive Officer, Deputy Chairman and ...
Total Annual Compensation: CNY6.0M
Co-Founder and Executive Chairman
Total Annual Compensation: CNY10.0M
Deputy General Manager of Sales & Marketing a...
Total Annual Compensation: CNY4.0M
Compensation as of Fiscal Year 2016.
sihuan pharmaceutical hldgs
Sihuan Pharmaceutical Holdings Group Ltd. Declares Interim Dividend for the Six Months Ended June 30, 2017, Payable on or Around September 13, 2017

The board of Sihuan Pharmaceutical Holdings Group Ltd. has resolved to declare an interim dividend of 1.8 RMB cents per share for the six months ended June 30, 2017 compared to 1.4 RMB cents per share paid a year ago. The interim dividend will be payable on or around September 13, 2017 to the shareholders of the company whose names appear on the register of members of the company at the close of business on September 7, 2017.

Sihuan Pharmaceutical Holdings Group Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017

Sihuan Pharmaceutical Holdings Group Ltd. reported unaudited consolidated earnings results for the six months ended June 30, 2017. For the period, the company reported, revenue of HKD 1,440,310,000, operating profit of HKD 968,220,000, profit before income tax of HKD 997,186,000, profit for the period attributable to owners of the company of HKD 842,456,000, net cash flows from operating activities of HKD 902,712,000, purchases of items of property, plant and equipment of HKD 195,294,000, purchase of intangible assets of HKD 14,467,000, compared to revenue of HKD 1,387,672,000, operating profit of HKD 877,909,000, profit before income tax of HKD 890,468,000, profit for the period attributable to owners of the company of HKD 735,968,000, net cash flows from operating activities of HKD 1,060,790,000, purchases of items of property, plant and equipment of HKD 101,714,000, purchase of intangible assets of HKD 32,679,000, for the same period a year ago. Basic and diluted earnings per share attributable to ordinary equity holders of the company were 8.87 cents against 7.10 cents a year ago.

Sihuan Pharmaceutical Holdings Group Ltd. Announces Establishment of United States Research and Development Centre

The board of directors of Sihuan Pharmaceutical Holdings Group Ltd. announced that the group has recently set up its United States Research and Development Centre ("U.S. R&D Centre" or the "Center") in the San Francisco Bay Area in California of the United States (the "U.S.") after two years of planning. The establishment of Sihuan Pharmaceutical's U.S. R&D Centre is an important step on the road to the Group's global strategic planning. As a center of global biomedical technology, the San Francisco Bay Area has a concentration of top talent and advanced concept for innovative drug R&D. The Center will make full use of local talent and contract research organizations, and primarily focus on the development of immuno-oncology drugs, including small molecule drugs and large molecule biological drugs such as antibodies and fusion protein drugs. All the researchers and consultants of the Center are senior scientists with extensive experiences in innovative drug R&D. There are multiple projects under development currently. Sihuan Pharmaceutical's U.S. R&D Centre will work closely with and complement the Group's existing R&D platforms. On one hand, after finishing preclinical research of the drugs in the U.S., the Center will work with the Group's R&D platforms in China, in where sample production and clinical development will be conducted, in order to achieve effective resources utilization. On the other hand, the Center will make flexible adjustments to its R&D strategy based on government policies, regulations and the market environment. For instance, the Group plans to promote internationalization of its products through commencing clinical trials and registration process in the U.S. and China simultaneously. Meanwhile, it is expected to accelerate marketization of the products in China. This will further enhance the Group's pace and level of innovative drug R&D, thus fulfil unmet clinical demands. The establishment of Sihuan Pharmaceutical's U.S. R&D Centre leads the Group to the field of biological drug R&D, including antibodies and fusion protein drugs, and connects the Group to global leading R&D resources which boosts the Group's R&D development and is expected to bring high-level international cooperation opportunities, thus pave the way to the Group's international business expansion.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

460 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 460.
View Industry Companies
 

Industry Analysis

460

Industry Average

Valuation 460 Industry Range
Price/Earnings 14.0x
Price/Sales 7.7x
Price/Book 2.3x
Price/Cash Flow 13.7x
TEV/Sales 6.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SIHUAN PHARMACEUTICAL HLDGS, please visit www.sihuanpharm.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.